Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls

Ivy H Song, Julie Borland, Paul M Savina, Shuguang Chen, Parul Patel, Toshihiro Wajima, Amanda F Peppercorn, Stephen C Piscitelli, Ivy H Song, Julie Borland, Paul M Savina, Shuguang Chen, Parul Patel, Toshihiro Wajima, Amanda F Peppercorn, Stephen C Piscitelli

Abstract

This study evaluated dolutegravir pharmacokinetics (PK) in subjects with moderate hepatic impairment compared to matched, healthy controls. In this open-label, parallel-group study, eight adult subjects with moderate hepatic impairment (Child-Pugh Score 7-9) and eight healthy subjects matched for gender, age, and body mass index received a single dolutegravir 50-mg dose. Following dosing, 72-hour PK sampling was performed to determine total and unbound dolutegravir concentrations. PK parameters were calculated using non-compartmental analysis. Geometric least squares mean ratios (GMR) and 90% confidence intervals (CIs) in subjects with hepatic impairment versus healthy subjects were generated by analysis of variance. Results showed that PK parameters of total plasma dolutegravir were similar between subject groups. The unbound fraction was higher in subjects with moderate hepatic impairment than in healthy subjects with GMR (90% CI) of 2.20 (1.62, 2.99) for unbound fraction at 3 hours post-dose and 1.76 (1.23, 2.51) for unbound fraction at 24 hours post-dose; this correlated with lower serum albumin concentrations and was not considered clinically significant. Dolutegravir was well tolerated in both groups; all adverse events were reported as minor. Although free fraction was increased, no dose adjustment is required for patients treated with dolutegravir who have mild to moderate hepatic impairment.

Keywords: dolutegravir; hepatic impairment; pharmacokinetics; protein binding.

Figures

Figure 1
Figure 1
Mean plasma dolutegravir linear concentration-time plots. Error bars represent standard deviation.

References

    1. Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr. 2010;53:124–130.
    1. Smith C, Sabin CA, Lundgren JD, et al. Data collection on adverse events of Anti-HIV drugs (D:A:D) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS. 2010;24:1537–1548.
    1. Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis. 2008;197:S279–S293. (Suppl. 3):
    1. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med. 2007;356:1445–1454.
    1. Tedaldi E, Peters L, Neuhaus J, et al. SMART Study Group and International Network for Strategic Initiatives in Global HIV Trials (INSIGHT). Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. Clin Infect Dis. 2008;47:1468–1475.
    1. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64:1147–1161.
    1. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis. 2005;40:174–181.
    1. Song I, Borland J, Chen S , et al. Metabolism and drug-drug interaction profile of dolutegravir (DTG, S/GSK1349572). Presented at: 13th International Workshop on Clinical Pharmacology of HIV Therapy; April 16–18, 2012; Barcelona, Spain. Abstract O-07.
    1. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649.
    1. Lucey MR, Brown KA, Everson GT, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg. 1997;3:628–637.
    1. Food and Drug Administration . Pharmacokinetics in patients with impaired hepatic function: study design, data analysis and impact on dosing and labeling. Published May 2003. Accessed May 14, 2013.
    1. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377:1198–1209.
    1. Hoyumpa AM, Schenker S. Is glucuronidation truly preserved in patients with liver disease. Hepatology. 1991;13:786–795.
    1. Debinski HS, Lee CS, Danks JA, Mackenzie PI, Desmond PV. Localization of uridine 5′-diphosphate-glucuronosyltransferase in human liver injury. Gastroenterology. 1995;108:1464–1469.
    1. Furlan V, Demirdjian S, Bourdon O, Magdalou J, Taburet AM. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. J Pharmacol Exp Ther. 1999;289:1169–1175.
    1. Letendre S, Mills A, Tashima K , et al. Distribution and antiviral activity in cerebrospinal fluid (CSF) of the integrase inhibitor, dolutegravir (DTG): ING116070 week 16 results. Presented at: 20th Annual Conference on Retroviruses and Opportunistic; March 3–6, 2013; Atlanta, GA. Abstract 178LB.
    1. Raffi F, Rachlis A, Stellbrink H-J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735–743.
    1. Walmsley S, Antela A, Clumeck N , et al. Dolutegravir (DTG; S/GSK1349572) plus abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results from SINGLE (ING114467). Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9–12, 2012; San Francisco CA. Abstract H-556b.
    1. Pozniak A, Mingrone H, Shuldyakov A , et al. Dolutegravir (DTG) versus raltegravir (RAL) in ART-experienced, integrase naïve subjects: 24-week interim results from SAILING (ING111762). Presented at: 20th Annual Conference on Retroviruses and Opportunistic Infections; March 3–6, 2013; Atlanta, GA. Abstract 179LB.
    1. Nichols G, Mills A, Grossberg R , et al. Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING -3. Presented at: 11th International Congress on Drug Therapy in HIV Infection; November 11–15, 2012; Glasgow, UK. Abstract O232.
    1. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55:813–821.
    1. Elbekai RH, Korashy HM, El-Kadi AO. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab. 2004;5:157–167.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever